# RI Study to Assess and Compare the Pharmacokinetic Parameters of MD1003 in Renal Impaired Patients and Healthy Subjects

> **NCT04252430** · PHASE1 · TERMINATED · sponsor: **MedDay Pharmaceuticals SA** · enrollment: 24 (actual)

## Conditions studied

- Healthy Volunteers
- Impaired Renal Function

## Interventions

- **DRUG:** MD1003

## Key facts

- **NCT ID:** NCT04252430
- **Lead sponsor:** MedDay Pharmaceuticals SA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-10-09
- **Primary completion:** 2020-03-17
- **Final completion:** 2020-03-17
- **Target enrollment:** 24 (ACTUAL)
- **Why stopped:** Due to other phase 3 trial failure to meet primary endpoint
- **Last updated:** 2020-05-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04252430

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04252430, "RI Study to Assess and Compare the Pharmacokinetic Parameters of MD1003 in Renal Impaired Patients and Healthy Subjects". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04252430. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*